Participants 50 148 8
advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials
Participants 255 368 10
advanced or recurrent endometrial cancer patients participating in Gynecologic Oncology Group chemotherapy trials
Participants 912 965 5
1203 patients treated on 4 randomized clinical trials
Participants 1140 1292 4
More S/CC patients enrolled on trials with advanced stage (III-IV) disease (as opposed to recurrent disease) compared to E patients (45% vs. 24%, p<0.05
Participants 1684 1735 3
patients with advanced/recurrent endometrial cancer
